- Home
- GANX vs CVM Comparison
GANX vs CVM Comparison
Compare GANX & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- CVM
- Stock Information
- Founded
- GANX 2017
- CVM 1983
- Country
- GANX United States
- CVM United States
- Employees
- GANX N/A
- CVM N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GANX Health Care
- CVM Health Care
- Exchange
- GANX Nasdaq
- CVM Nasdaq
- Market Cap
- GANX 53.8M
- CVM N/A
- IPO Year
- GANX 2021
- CVM 1987
- Fundamental
- Price
- GANX $1.77
- CVM $2.50
- Analyst Decision
- GANX Strong Buy
- CVM
- Analyst Count
- GANX 5
- CVM 0
- Target Price
- GANX $8.20
- CVM N/A
- AVG Volume (30 Days)
- GANX 324.3K
- CVM 242.4K
- Earning Date
- GANX 08-07-2025
- CVM 08-14-2025
- Dividend Yield
- GANX N/A
- CVM N/A
- EPS Growth
- GANX N/A
- CVM N/A
- EPS
- GANX N/A
- CVM N/A
- Revenue
- GANX N/A
- CVM N/A
- Revenue This Year
- GANX N/A
- CVM N/A
- Revenue Next Year
- GANX N/A
- CVM N/A
- P/E Ratio
- GANX N/A
- CVM N/A
- Revenue Growth
- GANX N/A
- CVM N/A
- 52 Week Low
- GANX $0.89
- CVM $1.98
- 52 Week High
- GANX $3.19
- CVM $66.60
- Technical
- Relative Strength Index (RSI)
- GANX 44.01
- CVM 37.73
- Support Level
- GANX $1.55
- CVM $2.21
- Resistance Level
- GANX $2.04
- CVM $2.50
- Average True Range (ATR)
- GANX 0.16
- CVM 0.21
- MACD
- GANX -0.02
- CVM 0.17
- Stochastic Oscillator
- GANX 28.34
- CVM 66.15
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.